RT Journal Article
SR Electronic
T1 Trans-ethnic Genomic Informed Risk Assessment for Alzheimer’s disease: An International Hundred K+ Cohorts Consortium Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.22.22283738
DO 10.1101/2022.12.22.22283738
A1 Sleiman, Patrick M.
A1 Qu, Hui-Qi
A1 Connolly, John J
A1 Mentch, Frank
A1 Pereira, Alexandre
A1 Lotufo, Paulo A
A1 Tollman, Stephen
A1 Choudhury, Ananyo
A1 Ramsay, Michele
A1 Kato, Norihiro
A1 Ozaki, Kouichi
A1 Mitsumori, Risa
A1 Jeon, Jae-Pil
A1 Hong, Chang Hyung
A1 Son, Sang Joon
A1 Roh, Hyun Woong
A1 Lee, Dong-gi
A1 Mukadam, Naaheed
A1 Foote, Isabelle F
A1 Marshall, Charles R
A1 Butterworth, Adam
A1 Prins, Bram P
A1 Glessner, Joseph T
A1 Hakonarson, Hakon
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/12/22/2022.12.22.22283738.abstract
AB Background Alzheimer’s disease (AD) is a complex multifactorial progressive dementia affecting all human populations. As a collaboration model between the International Hundred K+ Cohorts Consortium (IHCC) and the Davos Alzheimer Collaborative (DAC), our aim was to develop a trans-ethnic genomic informed risk assessment (GIRA) algorithm for AD.Methods The GIRA model was created to include a polygenic risk score (PRS) calculated from the AD GWAS loci, the APOE haplotypes, and non-genetic covariates including age, sex and first 3 principal components of population substructure. The model was first validated using a ancestrally diverse dataset from the eMERGE network, and subsequently validated in a South-Asian population in the UK and 3 East-Asian populations. The distributions of the PRS scores were also explored in populations from 3 African regions. In two validation sites, the PRS was tested for associated with the levels of plasma proteomics markers.Results We created a trans-ethnic GIRA model for the risk prediction of AD and validated the performance of the GIRA model in different populations. The proteomic study in the participant sites identified proteins related to female infertility and autoimmune thyroiditis and associated with the risk scores of AD, highlighting molecular mechanisms underlying the previously observed correlations between these clinical phenotypes.Conclusions As the initial effort by the IHCC to leverage existing large scale datasets in a collaborative setting with DAC, we developed a trans-ethnic GIRA for AD with the potential of identifying individuals at high risk of developing AD for future clinical applications. The PRS scores in this model also contribute new research discoveries for the molecular pathogenesis of AD as demonstrated by the proteomic data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by: All authors were supported by the International HundredK+ Cohorts Consortium (IHCC), which was created in collaboration with the Global Alliance for Genomics and Health (GA4GH) and the Global Genomics Medicine Collaborative (G2MC) with support from the National Institute of Health and the Wellcome Trust. The Davos Alzheimer Collaborative (DAC) provided funding to enable completion the study. The study was funded in part by an Institutional Development Fund from the Children's Hospital of Philadelphia to the Center for Applied Genomics, and The Children's Hospital of Philadelphia Endowed Chair in Genomic Research. ELSA-Brasil is funded by the Brazilian Ministry of Health (Department of Science and Technology) and the Ministry of Science, Technology and Innovation (FINEP, Financiadora de Estudos e Projetos), and CNPq (the National Council for Scientific and Technological Development). Genes & Health has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. Korea Biobank and Biobank Innovations for Chronic cerebrovascular disease With ALZheimer's disease Study (BICWALZS) are funded by the Korea Disease Control and Prevention Agency for the Korea Biobank Project (#6673-303). Participants in the INTERVAL randomized controlled trial were recruited with the active collaboration of NHS Blood and Transplant (www.nhsbt.nhs.uk), which has supported fieldwork and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR Cambridge Biomedical Research Centre (BRC) (no. BRC-1215-20014). The academic coordinating centre for INTERVAL was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (no. NIHR BTRU-2014-10024), UK Medical Research Council (MRC) (no. MR/L003120/1), British Heart Foundation (nos SP/09/002, RG/13/13/30194 and RG/18/13/33946) and the NIHR Cambridge BRC (no. BRC-1215-20014). A complete list of the investigators and contributors to the INTERVAL trial is provided in ref.17. The academic coordinating centre thanks blood donor centre staff and blood donors for participating in the INTERVAL trial. This work was supported by Health Data Research UK, which is funded by the UK MRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The views expressed in this manuscript are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The AWI-Gen Study was funded by the National Human Genome Research Institute (NHGRI), Office of the Director (OD), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), the National Institute of Environmental Health Sciences (NIEHS), the Office of AIDS research (OAR) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH) under award number U54HG006938. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempted by the Institutional Review Board (IRB) of the Children's Hospital of Philadelphia, USA. Human participant personal information was not shared with the research group and participants were de-identification. All human participants or their proxies provided written informed consent for their respective studies and all the studies were approved by their local and/or national ethics review boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupporting data from this study can be obtained by emailing the corresponding author Dr. Hakon Hakonarson.